ARMP (Armata Pharmaceuticals) Debt-to-Equity : -2.75 (As of Sep. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Armata Pharmaceuticals Debt-to-Equity?

Armata Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $112.40 Mil. Armata Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $27.93 Mil. Armata Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-50.97 Mil. Armata Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2024 was -2.75.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Armata Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ARMP' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.17 Med: 0.29 Max: 3.57
Current: -2.75

During the past 13 years, the highest Debt-to-Equity Ratio of Armata Pharmaceuticals was 3.57. The lowest was -9.17. And the median was 0.29.

ARMP's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ARMP: -2.75

Armata Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Armata Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Debt-to-Equity Chart

Armata Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.20

0.70

1.50

1.35

-3.75

Armata Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															-9.17	-3.75	-2.97	-3.17	-2.75

Competitive Comparison of Armata Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Armata Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Debt-to-Equity falls into.

Armata Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Armata Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.481	+	110.89)	/	-32.065
	=	-3.75

Armata Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(112.397	+	27.929)	/	-50.973
	=	-2.75

Armata Pharmaceuticals (AMEX:ARMP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Armata Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Armata Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (AMEX:ARMP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TG1M:Germany TG1N:Germany

Address

5005 McConnell Avenue, Los Angeles, CA, USA, 90066

Website

https://www.armatapharma.com

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Executives

Richard Rychlik	officer: Corporate Controller and PFO	5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx	director, officer: Chief Executive Officer	3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill	officer: Chief Financial Officer	361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler	officer: Vice President,Finance & Admin	4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc	director, 10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer	director	999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin	officer: Chief Financial Officer	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook	director	TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson	director	C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker	director